Alder BioPharma (ALDR) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to Alder BioPharma (ALDR) Misses Q2 EPS by 4c

Alder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results

July 26, 2016 4:06 PM EDT

Positive 24-Week Clinical Data for ALD403 in Chronic Migraine Continues to Demonstrate a Best-In-Class Profile as Company Advances Toward a BLA Submission

Advances Second Program Directed at Migraine Prevention, ALD1910, into IND-Enabling Studies

BOTHELL, Wash., July 26, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today provided a corporate update and reported its financial and operating results for the second quarter ended June 30, 2016.

Led by the positive top-line 24 week data in chronic migraine announced... More